European Biotech Acquisition Corp.
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of European Biotech Acquisition Corp. generated cash of -$514,792, which is more than the previous year. Cash used in financing activities reached the amount of -$45,000 last year. Net change in cash is therefore -$559,792.
Cash Flow
| 2021 | -688.83K | -127.54M | 129.10M |
|---|---|---|---|
| 2022 | -514.79K | 0 | -45K |
EBAC Cash Flow Statement (2021 – 2022)
| 2022 | 2021 | |
|---|---|---|
Cash at beginning of period | 868.28K | 0 |
Operating activities | ||
Net income | 342.89K | 1.47M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||
Depreciation and amortization | 0 | 0 |
Stock-based compensation expense | 0 | 0 |
| Deferred income tax benefit | 0 | 0 |
| Changes in operating assets and liabilities: | ||
Accounts receivable, net | 0 | 0 |
Inventories | 0 | 0 |
Accounts payable | 301.63K | 57.90K |
Cash generated by operating activities | -514.79K | -688.83K |
Investing activities | ||
Purchases Of Investments | 0 | 0 |
Investments In Property Plant And Equipment | 0 | 0 |
Acquisitions Net | 0 | 0 |
Cash generated by investing activities | 0 | -127.54M |
Financing activities | ||
Common Stock Issued | 0 | 132.09M |
Payments for dividends | 0 | 0 |
Repurchases of common stock | 0 | 0 |
Repayments of term debt | 0 | -37.80K |
Cash used in financing activities | -45K | 129.10M |
Net Change In Cash | -559.79K | 868.28K |
Cash at end of period | 308.48K | 868.28K |
| Data source | Data source |